688799.SH
华纳药厂
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 43.33
−0.73%Year over year
Reported trailing growth
- Revenue
- +8.4%
- EBITDA
- —
- EBIT
- +61.2%
- EPS
- +53.9%
- Free cash flow
- -66.2%
- Operating cash flow
- +164.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.2%
- EBITDA
- +9.0%
- EBIT
- +7.1%
- Net income
- +9.2%
- EPS
- -2.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026